Jubilant Pharmova Q2 Results Live : Jubilant Pharmova declared their Q2 results on October 25, 2024, revealing a notable increase in profitability. The company’s topline surged by 4.28% year-over-year, while profits skyrocketed by 64.48%. Despite the positive year-over-year results, there was a slight decline compared to the previous quarter, where revenue experienced a growth of only 1.19% and profit saw a significant drop of 78.68%.
In terms of expenses, the Selling, General & Administrative expenses increased by 2.06% quarter-over-quarter and rose by 6.11% year-over-year. This uptick in expenses may have contributed to the reduction in operating income, which was down by 66.98% from the previous quarter, though it did see an increase of 26.58% year-over-year.
The Earnings Per Share (EPS) for Q2 was reported at ₹7.09, reflecting an impressive growth of 80.04% compared to the same quarter last year. Investors might find this figure encouraging as it indicates a solid increase in profitability on a per-share basis.
In the past week, Jubilant Pharmova has faced a slight dip, delivering a return of -5.57%. However, the company has shown a remarkable recovery over a longer timeframe, with a return of 63.48% over the last six months and an impressive 103.14% year-to-date. This performance has led to a market capitalization of ₹17,551.15 Cr, with a 52-week high of ₹1247.15 and a low of ₹318.75.
Looking ahead, the sentiment among analysts remains positive. As of October 26, 2024, out of three analysts covering the company, one has given a ‘Buy’ rating while two have assigned a ‘Strong Buy’ rating. The consensus recommendation is to ‘Strong Buy’, indicating confidence in the company’s future performance.
Jubilant Pharmova Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 1752.3 | 1731.7 | +1.19% | 1680.3 | +4.28% |
| Selling/ General/ Admin Expenses Total | 564.3 | 552.9 | +2.06% | 531.8 | +6.11% |
| Depreciation/ Amortization | 91.4 | 90.7 | +0.77% | 96.6 | -5.38% |
| Total Operating Expense | 1568.5 | 1175 | +33.49% | 1535.1 | +2.18% |
| Operating Income | 183.8 | 556.7 | -66.98% | 145.2 | +26.58% |
| Net Income Before Taxes | 144.4 | 499.7 | -71.1% | 98 | +47.35% |
| Net Income | 102.8 | 482.1 | -78.68% | 62.5 | +64.48% |
| Diluted Normalized EPS | 7.09 | 6.34 | +11.92% | 3.94 | +80.04% |
